Benzinga | Oct 11, 2021 11:14AM EDT

Morgan Stanley Upgrades Prelude Therapeutics to Overweight, Lowers Price Target to $35

Morgan Stanley upgrades Prelude Therapeutics (NASDAQ:PRLD) from Equal-Weight to Overweight and lowers the price target from $60 to $35.